

Tissue Accumulation of Neutrophil Extracellular Traps Mediates Muscle Hyperalgesia in a Mouse Model

Kazuaki Suzuki

Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Japan

Masahiro Tsuchiya (✉ tsuchiya-thk@umin.ac.jp)

Tohoku Fukushi University

Shinichiro Yoshida

Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Japan

Kazumi Ogawa

Tohoku University Graduate School of Biomedical Engineering

Weijian Chen

Tohoku University Graduate School of Biomedical Engineering

Makoto Kanzaki

Tohoku University Graduate School of Biomedical Engineering

Tadahisa Takahashi

Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Japan

Ryo Fujita

Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Japan

Yuqing Li

Tohoku University Graduate School of Biomedical Engineering

Yutaka Yabe

Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Japan

Toshimi Aizawa

Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Japan

Yoshihiro Hagiwara

Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Japan

Research Article

Keywords: neutrophil extracellular trap, uric acid, muscle pain, citrullinated histone H3, multiphoton microscopy imaging

Posted Date: July 23rd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-576628/v2>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Scientific Reports on March 9th, 2022. See the published version at <https://doi.org/10.1038/s41598-022-07916-8>.

1 **Tissue accumulation of neutrophil extracellular traps mediates muscle**

2 **hyperalgesia in a mouse model**

3

4 Kazuaki Suzuki^{1,2}, Masahiro Tsuchiya^{3*}, Shinichiro Yoshida¹, Kazumi Ogawa^{1,2}, Weijian

5 Chen², Makoto Kanzaki², Tadahisa Takahashi^{1,2}, Ryo Fujita^{1,2}, Yuqing Li^{1,2}, Yutaka Yabe¹,

6 Toshimi Aizawa¹, and Yoshihiro Hagiwara¹

7

8 ¹ Department of Orthopaedic Surgery, Graduate School of Medicine, Tohoku University,

9 Sendai, Japan

10 ² Graduate School of Biomedical Engineering, Tohoku University, Sendai, Japan

11 ³ Department of Nursing, Tohoku Fukushi University, Sendai, Miyagi, Japan

12

13 ****Corresponding author***

14 Masahiro Tsuchiya, DDS., PhD.

15 Department of Nursing, Tohoku Fukushi University

16 6-149-1 Kunimi-ga-oka, Sendai 981-3201, Japan

17 Tel: +81-22-728-6049, Fax: +81-22-233-3113

18 E-mail: tsuchiya-thk@umin.ac.jp

19

20

21 **Abstract**

22 Accumulation of uric acid (UA) during muscular trauma is a causative factor involved in
23 the development of muscle hyperalgesia. Neutrophil extracellular traps (NETs), DNA-
24 based reticular structures to capture UA, play a central role in the pain onset of gout
25 attacks; however, the involvement of NETs via the elevation of local UA level in muscle
26 hyperalgesia due to overuse injuries remains unknown. The triceps surae muscles (TSMs)
27 in the unilateral hindlimb of mice were electrically stimulated to induce excessive muscle
28 contraction. Mechanical withdrawal thresholds, tissue UA levels, neutrophil recruitment,
29 protein amount of citrullinated histone 3 (citH3), a major marker of NETs, were
30 investigated. Furthermore, whether neutrophil depletion, extracellular DNA cleavage, and
31 administration of the urate-lowering agent febuxostat could improve muscle hyperalgesia
32 due to NET formation was examined. CitH3 expression upon neutrophil recruitment
33 significantly increased in the stimulated TSMs with an increase in tissue UA levels,
34 whereas febuxostat administration improved muscle hyperalgesia with decreases in citH3
35 and tissue UA levels, as observed in neutrophil depletion and extracellular DNA digestion.
36 The underlying mechanism of muscle hyperalgesia associated with locally recruited
37 neutrophils forming NETs due to the increased tissue UA levels potentially plays a
38 significant role in creating a vicious circle of muscle pain.

39 **Keywords:** neutrophil extracellular trap, uric acid, muscle pain, citrullinated histone H3,
40 multiphoton microscopy imaging

41

42 **Introduction**

43 Skeletal muscle is a common source of pain that markedly impairs activities of daily
44 living ¹. It is widely observed as a major sign of various pathologies, such as neck and
45 shoulder pain ², nonspecific lower back pain ³, and myofascial pain syndrome (MPS) ⁴.

46 Based on the higher lifetime prevalence of skeletal muscle pain among the labor
47 population ^{5,6}, muscle overuse is a key pathogenic event in developing muscle pain.

48 Fundamentally, overuse trauma prompts muscle fibers to release extracellular adenosine
49 triphosphate (ATP), which directly activates pain signaling through purinergic and
50 metabotropic receptors via autocrine and paracrine functions ^{7 8 9 10}. Indeed, both the
51 serum and muscle tissue levels of uric acid (UA), an end product of purine nucleotides
52 including ATP and dead cell DNA, are reportedly increased due to the production of
53 damaged muscle fibers ^{11,12 13-15}.

54 UA has recently been recognized as a damage-associated molecular pattern (DAMP),
55 which activates an intracellular complex called the inflammasome for processing and
56 releasing interleukin (IL)-1 β and IL-18 ¹⁶. Our recent study using a muscle pain model by

57 the repeated electrical stimulation of the triceps surae muscles (TSMs) revealed the
58 marked recruitment of inflammatory cells, including neutrophils and macrophages,
59 producing proinflammatory cytokines, such as IL-1 β and IL-18; this was due to
60 inflammasome activation, which was triggered by the increase in tissue UA levels^{11 15 17}.
61 Furthermore, based on the improvement of muscle hyperalgesia by the administration of
62 xanthine oxidase inhibitors, we suggested that a higher tissue UA concentration could be
63 a causative factor of mechanical hyperalgesia¹¹. Thus, the dysregulated innate immune
64 response with hyperuricemia has been associated with gout among various
65 autoinflammatory diseases; these autoinflammatory diseases are characterized by
66 unprovoked episodes of recurrent or continuous inflammation in the absence of high-titer
67 autoantibodies or antigen-specific lymphocytes^{18 19 20}.

68 A recent study has also supported that the dysregulated innate immune response of
69 neutrophils against monosodium urate (MSU) crystals in the gout flare is a part of the
70 autoinflammatory response because of the involvement of neutrophil extracellular traps
71 (NETs)²¹. The release of NETs, a unique defense mechanism continuing from cell death
72 (NETosis), is regarded as a valuable target for disease pathogenesis in gout^{21 22 23}. NETs
73 are primarily composed of their own DNA released as reticular structures with an
74 oxidative burst in order to capture and eliminate pathogens, including DAMPs^{22 23}, and

75 citrullinated histone H3 (citH3) plays a central role in NETosis. Interestingly, NETs also
76 contribute to aggregating neutrophilic proinflammatory mediators, thereby limiting, but
77 prolonging the inflammatory status ²². Indeed, NETs are not only a DAMP after
78 degradation, but also a potential source of UA with extracellular nucleotide metabolism
79 ²³. Thus, research findings regarding the underlying mechanism of UA accumulation with
80 a focus on NETs in damaged muscle tissues will facilitate the development of an
81 integrative therapeutic strategy for chronic muscle pain.

82 Although the involvement of NET-mediated processes in numerous painful diseases,
83 including gout and rheumatoid arthritis, has been reported ^{21 22}, no reports have described
84 the relationship between NETs and muscle pain. Therefore, using a muscle pain model
85 with muscle overuse, we examined whether neutrophils play a key role in developing
86 muscle pain via NET production triggered by increased UA levels.

87

88 **Results**

89 **MSU stimulation induces NETs and muscle pain in the TSMs**

90 To investigate whether MSU crystals induced NETs in skeletal muscle tissues, as shown
91 in previous studies, we first performed the intramuscular injection of MSU by following
92 a method reported in our previous study (Fig. 1) ¹¹. Compared to those of the control

93 group, the MNTs of the MSU group significantly decreased after the intramuscular
94 injection of MSU (Fig. 1a). In terms of IHC observations, control TSMs with saline
95 injection did not show any changes, whereas the increased immunoreactivity of citH3 and
96 Gr-1 was located around the outer edge of MSU (Fig. 1b). Western blotting using the
97 TSM tissues stimulated with MSU on day 2 showed significant increases in citH3 (Fig.
98 1c) and Ly6G (Fig. 1d). Additionally, IL-1 β expression in the TSMs injected with MSU
99 significantly increased on day 2 (Fig. 1e).

100

101 **Excessive muscle contraction caused by repeated EPS induced mechanical**
102 **hyperalgesia with elevated NET production in the skeletal muscle tissues**

103 We next confirmed whether excessive muscle contraction by EPSs induced NET
104 formation associated with an increase in tissue UA levels (Fig. 2). As previously shown
105 in our studies ^{11,17}, the MNTs of the stimulated TSMs significantly decreased due to
106 repeated stimulation, compared to those of the contralateral muscle, and were
107 significantly decreased, with the minimum MNT noted on day 7 (Fig. 2a). Reduced MNTs
108 in the stimulated TSMs increased again after 7 consecutive days of electrical stimulation,
109 and MNTs between the control (non-stimulated) and MSU (stimulated) groups were not
110 significant on day 11 (Fig. 2a). The tissue samples on day 7 were mainly used in our

111 analyses based on the above results. Among the TSM samples on day 7, tissue UA levels
112 in the stimulated TSMs were significantly higher than those in the contralateral TSMs
113 (Fig. 2b).

114 IHC analysis indicated distinct distribution patterns of citH3 immunoreactivities,
115 which colocalized with Ly6G immunoreactivities in the stimulated TSMs, but not in the
116 non-stimulated TSMs (Fig. 2c). Hematoxylin and eosin staining showed typical skeletal
117 muscle tissue histology in both groups (data not shown). Further confirming these
118 observations, western blotting indicated that the relative density of citH3 (Fig. 2d) and
119 Ly6G (Fig. 2e) normalized to the loading control (total H3 and GAPDH, respectively)
120 were significantly increased in the stimulated TSMs on day 7 compared with those in the
121 non-stimulated TSMs. The time-series experiment of citH3 protein in comparison with
122 ipsilateral to contralateral TSM tissues during and after EPS is shown in Fig. 2f. The
123 protein amount ratio of citH3 showed the highest value on day 7 with repeated EPS,
124 whereas it recovered to the level on day 0 after stopping the stimulation. IL-1 β mRNA
125 expression was significantly increased in the stimulated TSMs than in the non-stimulated
126 TSMs (Fig. 2g).

127

128 **DNase treatment ameliorated muscle hyperalgesia and NET induction owing to**

129 **repeated EPS**

130 To confirm the pathological significance of NETs in muscle hyperalgesia, we
131 administered DNase I to degrade extracellular DNA, including NETs, and demonstrated
132 its impact on muscle hyperalgesia (Fig. 3). Intravenous administration of DNase I
133 significantly increased the MNT values (Fig. 3a) and decreased tissue UA levels (Fig. 3b)
134 in the stimulated TSMs. Consistent with these observations, IHC (Fig. 3c) and western
135 blotting analyses (Fig. 3d and e) indicated that DNase I administration decreased the
136 citH3 expression, but not the protein concentration of Gr-1. Additionally, IL-1 β mRNA
137 expression in the stimulated TSMs decreased following DNase I administration (Fig. 3f).
138 Importantly, DNase administration reduced not only citH3, but also tissue UA levels
139 despite the same intensity and duration of the repeated EPS application.

140

141 **Neutrophil depletion ameliorated muscle hyperalgesia and NET induction owing to**

142 **repeated EPS**

143 Given the absolute necessity of neutrophil recruitment for NET induction, we next
144 examined the effects of an experimental neutrophil depletion by prior treatment with anti-
145 Gr-1 antibody on muscle hyperalgesia (Fig. 4). Neutrophil depletion resulted in a
146 significant increase of the MNT in the stimulated hindlimbs (Fig. 4a) and reduced tissue

147 UA levels (Fig. 4b) in the TSMs with repeated EPS. Similar to the IHC images showing
148 weaker immunoreactivity of citH3 and Gr-1 in the neutrophil-depleted group than in the
149 control group (Fig. 4c), neutrophil depletion significantly decreased the relative ratio of
150 citH3 (Fig. 4d) and IL-1 β mRNA expression (Fig. 4e) in the stimulated TSMs compared
151 with the control mice injected with the same amount of normal rat IgG. Notably, the tissue
152 UA level in the stimulated TSMs was decreased with experimental neutrophil depletion.

153

154 **Febuxostat treatment relieved muscle hyperalgesia due to repeated EPS**

155 Since our recent study reported that the decrease in tissue UA levels resulted in the
156 improvement of muscle hyperalgesia ¹¹, we investigated whether the administration of
157 febuxostat, a xanthine oxidase inhibitor, influenced NET induction due to repeated EPS
158 (Fig. 5). As reported in our previous study ¹¹, febuxostat treatment increased the MNTs
159 (Fig. 5a), and reduced tissue UA levels (Fig. 5b) and IL-1 β mRNA expression (Fig. 5f) in
160 the stimulated TSMs. Consistent with these observations, IHC (Fig. 5c) and western
161 blotting analyses indicated that febuxostat administration reduced citH3 expression (Fig.
162 5d), but not neutrophil recruitment (Fig. 5c and e) in the stimulated TSMs. These results
163 indicate that high tissue UA levels would play a central role in NET induction in skeletal
164 muscle tissues with hyperalgesia.

165

166 **MPM imaging with in vivo staining for NET-like structures**

167 To confirm that repeated EPS induced neutrophil recruitment with extracellular DNA
168 release in TSM tissues, MPM imaging was performed using an in vivo immunostaining
169 method ²⁴. As shown in Fig. 6 and Supplemental movie, repeated EPS significantly
170 increased the fluorescence of neutrophils and extracellular DNA in TSM tissues, as
171 visualized by QD655 and SYTOX, respectively. In particular, the myofascial region
172 showed significantly more fluorescence colocalizations than the TSM myofibers.

173

174 **Discussion**

175 The present study clarified the potential pathogenesis of NETs in muscle
176 hyperalgesia (exhibiting elicited nocifensive behaviors) due to a locally higher tissue UA
177 level caused by excessive muscle contraction (Fig. 2) as well as noted the observations in
178 the TSMs with MSU injection (Fig. 1). Our findings showed a potentially “vicious cycle”
179 model of muscle hyperalgesia due to a higher tissue UA level, which develops in a
180 reciprocal manner between neutrophil recruitment and NET induction (Fig. 7).

181 NETs play an essential function in immobilizing and killing pathogens, including
182 bacteria, whilst limiting inflammation, whereas inappropriate NET release has harmful

183 late effects on tissues due to the release of cytotoxic and proinflammatory mediators with
184 NET degradation^{22 23}. Delayed-onset muscle soreness, a typical muscle pain experienced
185 after excessive exercise, persists for a few days⁷. Based on the increased serum NET
186 levels after acute severe exercise²⁵, the characteristics of NETs would not only play a
187 crucial role in prolonging and strengthening local inflammation and pain, as observed in
188 our results, but also in general muscle physiology. Additionally, recent studies have
189 focused on the implications of NETs in numerous autoinflammatory diseases, including
190 systemic lupus erythematosus, psoriasis, and gout^{21 22 26}. Interestingly, our results also
191 demonstrated that febuxostat administration, as well as the experimental neutrophil
192 depletion and DNase administration, improved the local NET accumulation associated
193 with muscle hyperalgesia (Fig. 3). Febuxostat was reported to reduce not only tissue UA
194 content, but also neutrophil recruitment in damaged tissues²⁷. Thus, local NET
195 accumulation in skeletal muscles damaged by repeated excessive exercise would enhance
196 inflammation and pain with a sustainable supply of proinflammatory stimuli consisting
197 of inflammatory mediators, such as IL-1 β and DAMPs, including UA.

198 MSU crystallization due to hyperuricemia is a typical causative stimulus of acute
199 and painful inflammatory responses in gout attacks^{20 21}. Since our previous work showed
200 that a higher UA level in skeletal muscle tissues was a potential trigger for muscle

201 hyperalgesia ¹¹, we here indicated the involvement of NETs as a crucial mediator in
202 developing muscle hyperalgesia caused by a higher UA content in skeletal muscle tissues.
203 However, no MSU crystals were found in the skeletal muscle tissues with excessive
204 contraction. In terms of MSU crystallization, Martillo et al. indicated that 405 $\mu\text{mol/L}$ is
205 the solubility limit of the serum UA ²⁸. Our results showed that the average local UA
206 concentration (approximately 500 $\mu\text{mol/L}$) in the stimulated muscles was higher than the
207 abovementioned value. Because Braga et al. indicated that high concentrations of soluble
208 UA directly activate innate immunity ¹⁶, a higher tissue UA level possibly contributes to
209 the modulation of a microenvironment with a higher risk of NET induction as neutrophil
210 recruitment.

211 In terms of a vicious cycle of a higher tissue UA level leading to NET
212 accumulation and consequent development of muscle hyperalgesia (Fig. 7), both
213 neutrophil depletion (Fig. 4) and DNase treatment (Fig. 3) essentially resulted not only in
214 the improvement of muscle hyperalgesia, but also in the reduction of the tissue UA levels
215 in the damaged skeletal muscles, as well as the febuxostat treatment (Fig. 5). Based on
216 the activation of the inflammasome pathway in macrophages by a higher UA level ^{11 16},
217 the neutrophil–macrophage interactions, as the main innate immune response,
218 definitively contribute to the deterioration of muscle hyperalgesia. Although future

219 studies with appropriate designs are warranted to clarify the above aspects, these findings
220 suggest that extracellular DNA consisting of NETs with neutrophil recruitment is
221 potentially the main source inducing a higher UA level in skeletal muscle tissues via
222 purine metabolism and plays a role in exacerbating muscle hyperalgesia.

223 Furthermore, MPM imaging of NET-like structures showed that extracellular
224 DNA fragments were mostly colocalized with neutrophils, but not in the skeletal muscle
225 fibers. Shinoda et al. also reported no histological changes in the stimulated skeletal
226 muscle tissues under the same experimental conditions ¹⁰. Thus, a higher tissue UA
227 content with skeletal muscle overloading may predominantly depend on neutrophil
228 recruitment followed by NETosis. Furthermore, neutrophils releasing extracellular DNA
229 were predominantly recruited more in myofascial tissues than in muscle fibers (Fig. 6).
230 This is consistent with the multiple lines of evidence regarding the pathomechanisms
231 underlying the development of MPS with the characteristic irritable response in
232 myofascial tissues ¹⁵. Future studies are warranted to clarify the mechanisms that
233 dominantly recruit neutrophils in myofascial tissues, thus providing new insights
234 regarding MPS therapy and management.

235

236 **Conclusions**

237 Our findings of NET dynamics clarified the underlying mechanism of muscle
238 hyperalgesia associated with recruited neutrophils forming NETs, which potentially cause
239 a higher UA content in skeletal muscle tissues. Thus, the regulation of local UA
240 metabolism while focusing on NET induction would be a potential therapeutic target to
241 relieve muscle pain.

242

243 **Methods**

244 **Experimental animals**

245 Male BALB/c mice (5–7 weeks old) were used in this study (CLEA Japan, Tokyo, Japan).
246 The study was carried out in compliance with the ARRIVE guidelines. Further, the
247 experimental design, care, and use of the mice were performed according to the guidelines
248 for animal experiments at Tohoku University. Ethical approval for this study was obtained
249 from the Animal Research Committee of Tohoku University (approval number: 2019
250 MdA-070). The mice were kept in standard cages maintained in an air-conditioned room
251 at 23 °C ± 1 °C with a 12-h light–dark cycle with ad libitum access to standard food
252 pellets and tap water, in accordance with the National Standards Relating to the Care and
253 Management of Laboratory Animals and Relief of Pain (Notification No. 88 of the
254 Ministry of the Environment, Japan, April 28, 2006). General anesthesia was induced in

255 each mouse by the intraperitoneal injection of medetomidine (0.3 mg/kg; ZENOAQ,
256 Fukushima, Japan), midazolam (4.0 mg/kg; SANDZ, Tokyo, Japan), and butorphanol (5.0
257 mg/kg; Meiji Seika Pharma Co, Tokyo, Japan). Mice were sacrificed by cervical
258 dislocation under inhalation anesthesia with isoflurane (MSD Animal Health, Kenilworth,
259 NJ, USA).

260

261 **Repeated electrical stimulation of the triceps surae muscles**

262 Electrical pulse stimulation (EPS) was repeatedly applied to induce excessive muscle
263 contraction of the TSMs, as previously described^{10 11 17}. Two stainless electrodes (single-
264 stranded stainless steel wire, A-M system, Sequim, WA, USA) were transcutaneously
265 inserted into the proximal and distal ends of the TSMs on the dorsal surface of the
266 hindlimbs under anesthesia. EPS using a STG4004 multichannel system (MCS GmbH,
267 Reutlingen, Germany) was performed on the muscle at 10 Hz with a 10-V amplitude and
268 a 100- μ s pulse width for 30 min everyday (day 0 through day 6). The bilateral hindlimbs
269 were immobilized with full ankle dorsiflexion using a scotch tape to stabilize the static
270 muscle tension during EPS. Electrodes were also applied to the contralateral hindlimbs
271 without EPS. Within 24 h after the last EPS, the TSMs were collected, immediately frozen
272 in liquid nitrogen, and stored at -80 °C until assayed.

273

274 **Assessment of mechanical nociceptive thresholds**

275 The mechanical nociceptive threshold (MNT) was defined as the amount of pressure
276 required to evoke pain-related reactions such as vocalization, struggling, and hindlimb
277 withdrawal. The MNT was evaluated using the Randall–Selitto test (MK-201D Pressure
278 Analgesy-Meter, Muromachi Kikai Co., Tokyo, Japan)²⁹. The test was performed with a
279 cone-shaped, 2.6-mm-diameter tip attached to a scale with a display. Pressure, gradually
280 increasing at regular intervals (10 mmHg/s) with setting the cut-off value to be 300 mmHg,
281 was applied to the lateral side of the TSMs¹¹. Since circadian rhythm affects pain
282 sensitivity, all MNT measurements were performed in the morning. To avoid bias, the
283 MNT assessments were analyzed by an investigator who was blinded to the experimental
284 conditions.

285

286 **Local effect of monosodium urate stimulation**

287 To confirm the local effects of MSU on NET induction, recrystallized MSU (No. 133–
288 13432; Wako Pure Chemicals Industries, Osaka, Japan) dissolved in saline was
289 administered to the right TSMs (MSU group), as previously described^{30 31}. Saline was
290 administered to the contralateral TSMs (control group). The solution (100 µL) of

291 recrystallized MSU (200 µg) was injected under the fascia of the lateral head of the TSMs
292 using a 27-gauge needle. MNTs were assessed on days 0, 1, 2, and 4 post-injection. The
293 TSMs were obtained, frozen in liquid nitrogen, and stored at -80 °C until assayed.

294

295 **Pharmacological experiments related to neutrophil extracellular trap formation**

296 We administered deoxyribonuclease (DNase) I (Wako Pure Chemical Industries, Ltd.,
297 Osaka, Japan; 10 mg per kg body weight [BW] per day) through intravenous injection via
298 the tail vein³² or febuxostat (F0847, Tokyo Chemical Industry Co., Ltd., Tokyo, Japan; 5
299 mg per kg BW per day) through intraperitoneal injection³³. The control mice were
300 injected with the same volume of the control vehicle (saline) 15 min prior to the
301 experiment.

302 To deplete neutrophils, anti-granulocyte-differentiation antigen 1 (Gr-1; a major
303 neutrophil marker) antibody (RB6-8C5, rat IgG2b) purified from the culture supernatants
304 of a hybridoma (provided by Dr. R. Coffman) was intravenously administered into the
305 mice (Gr-1 group) once every 3 days at a dose of 5 mg/kg BW^{34,35}, because the injection
306 effectively causes neutropenia for at least a few days^{36,37}. The control mice were also
307 injected with an equivalent amount of normal rat IgG (Jackson Laboratories, Bar Harbor,
308 ME) (IgG group).

309

310 **Measurement of tissue uric acid levels**

311 The frozen muscles (30 mg) were homogenized in 300 μ L of lysis buffer (30 mM Tris,
312 100 mM sodium chloride, 1 mM ethylenediaminetetraacetic acid, 1% Triton X-100, 2.5
313 mM sodium fluoride, 2 mM sodium polyphosphate, 1 mM sodium orthovanadate, 1 mM
314 phenylmethylsulphonyl fluoride, 10 μ g/mL aprotinin, 1 μ g/mL pepstatin, and 5 μ g/mL
315 leupeptin) and then the lysate was centrifuged at 12,000 \times g for 15 min at 4 $^{\circ}$ C. The
316 supernatants were collected for the assay of tissue UA levels and western blotting. The
317 tissue UA levels were measured using an assay kit (Cayman Chemical Company, Ann
318 Arbor, USA) following the manufacturer's instructions.

319

320 **Quantitative reverse transcription polymerase chain reaction**

321 Total RNA was extracted from the TSM tissues using TRIzol (Molecular Research Centre
322 Inc., Cincinnati, OH, USA). cDNA was prepared using a Transcriptor First Strand cDNA
323 Synthesis Kit (Roche, Basel, Switzerland). The primer sequences used were as follows:
324 IL-1b: F5'-TGG TGG GGG TTC TCT GTG GTT-3' and R5'-TTG AGG CGG CTT TCT
325 TTG TCC-3' and EF1a1 (internal control primer): F5'-TCG CTT TGC TGT TCG TGA
326 C-3' and R5'-TGG GGT GGC AGG TGT TAG-3'. The relative expression levels of each

327 mRNA were calculated as a function of EF1a1 expression, as previously described^{11 17}.

328

329 **Immunohistochemistry**

330 The TSM tissues were snap-frozen in liquid nitrogen and embedded in a Tissue-Tek

331 OCT compound (Sakura Finetek, Tokyo, Japan). The cryosections were transversely cut

332 into 5- μ m thickness using a cryostat (CM1850; Leica, Nussloch, Germany) and

333 mounted on coated glass slides, followed by acetone fixation. After washing and

334 incubating with a blocking buffer (5% bovine serum albumin [BSA] in Tris-buffered

335 saline with 0.1% Tween-20) including 10% normal goat serum (Nichirei Biosciences

336 Inc., Tokyo, Japan) for 30 min. The slides were incubated with a polyclonal rabbit anti-

337 citH3 antibody (ab5103; 10 ng/mL; Abcam, Waltham, MA, USA) and anti-Gr-1

338 antibody (RB6-8C5, rat IgG2b; 10 ng/mL; BioLegend, San Diego, CA, USA) in a

339 blocking buffer for 2 h at room temperature (RT). Subsequently, the slides were

340 incubated for 1 h with an Alexa Fluor 488-conjugated goat anti-rabbit IgG (A-11034,

341 Life Technologies, Carlsbad, CA, USA; dilution, 1:750) for anti-citH3 and an Alexa

342 Fluor 555-conjugated goat anti-rat IgG (A-21434, Life Technologies; dilution, 1:750)

343 for Gr-1 at RT. After washing, the slides were incubated with 4,6-diamidino-2-

344 phenylindole (Sigma–Aldrich; dilution, 1:500) for nuclear staining. Images were

345 captured using a fluorescence microscope (Olympus FV1000; Olympus, Tokyo, Japan)
346 equipped with an oil-immersion objective lens (UApo/340 40×/NA 1.35). The images
347 were analyzed using Fiji/ImageJ software (NIH, Bethesda, MD, USA). At least three
348 images from each slide were captured at 200X magnification. To avoid bias, a few
349 animals were used for immunohistochemistry (IHC), and two slides/animals were
350 analyzed. After confirming the reproducibility, representative images were obtained.

351

352 **Immunoblotting**

353 The lysates extracted from the TSM tissues were adjusted to 4.0 mg/mL with a lysis buffer
354 using a BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). In brief,
355 30 µL of samples were loaded for 5%–12% SDS-polyacrylamide gel electrophoresis and
356 transferred to Immobilon-P polyvinylidene difluoride membranes (Merck, Kenilworth,
357 NJ, USA)³⁸. The protein-transferred membranes were blocked with 5% BSA in Tris-
358 buffered saline with 0.1% Tween-20 and then incubated at 4 °C overnight with anti-citH3
359 (ab5103; 2 µg/mL), anti-histone H3 (ab1791; 1 µg/mL; Abcam), anti-Ly6G (127602; 2
360 µg/mL; Biolegend), and anti- GAPDH (#2118; 1:1000 dilution; Cell Signaling, Beverly,
361 MA, USA). The membranes were washed, followed by incubation at RT for 1 h with
362 HRP-conjugated secondary antibodies (1:10,000 dilutions of #ab6734; Abcam; and

363 1:5,000 dilutions of #32460; Thermo Fisher Scientific). Next, a signal using a
364 chemiluminescence reagent, was obtained from SuperSignal West Femto Maximum
365 Sensitivity Substrate (Thermo Fisher Scientific), and the band intensity was detected
366 using the Image Quant TL system (GE Healthcare, Chalfont St Giles, UK).

367

368 **Multiphoton microscopy imaging using in vivo staining of NET-like structures**

369 To detect NETs through in vivo staining, two types of fluorescent reagents, anti-Gr-1
370 antibody conjugated to Qdot655 (QD-Gr-1Ab, 3.0 µg per mouse) to detect neutrophils
371 and SYTOX Green (Thermo Fisher Scientific, 1 µL of 5 mM solution per mouse) to detect
372 extracellular DNA, were used ^{38 39 24}, and anti-Gr-1 antibodies were prepared by
373 conjugation to Qdot 655 using the SAIWI rapid antibody labeling kit (Invitrogen). The
374 conjugated antibodies were purified using a size-exclusion column, and its concentration
375 was determined by measuring the absorbance at 679 nm. After 24 h from EPS on day 7,
376 QD-Gr-1Ab and SYTOX were intravenously injected at 20 min before animal sacrifice
377 under anesthesia. Mice were fixed by transcardiac perfusion with 4% paraformaldehyde
378 in PBS, and the TSM tissues were subjected to multiphoton microscopy (MPM) imaging.
379 An upright A1R-MP multiphoton microscope (Nikon) equipped with a Ti-sapphire laser
380 (Mai-Tai Deep See, Spectra-Physics), GaAsP non-descanned detectors, and a water-

381 immersion objective lens (CFP75 Apo LWD 25x/NA1.1) was used for image recording
382 with an excitation laser consistently set at 920 nm, with an area size of 510 $\mu\text{m} \times 510 \mu\text{m}$
383 and a resolution of 600 dpi. The wavelengths for detection using emission filter cubes
384 were 492/SP nm for second-harmonic generation signals (blue channel), 525 ± 50 nm for
385 SYTOX (green channel), and 629 ± 56 nm for QD-Gr-1Ab (far-red channel). By
386 distinguishing between the muscle and myofascial area based on the second-harmonic
387 generation signals indicating muscle and collagenous fibers ⁴⁰, we obtained the
388 fluorescence colocalization of QD-Gr-1Ab and SYTOX to quantitatively measure the
389 accumulation of NET-like structures in each area using ImageJ software ⁴¹. Further,
390 representative 3D image stacks focusing on neutrophil recruitment releasing extracellular
391 DNA were reconstructed from the sequential images in TSM structure.

392

393 **Statistical analysis**

394 Statistical analyses were performed using SPSS (IBM, Armonk, NY, USA). Analysis of
395 the MNT time-course data was performed using two-way analysis of variance (ANOVA),
396 and repeated measurements were compared using Tukey's post-hoc multiple-comparison
397 test. To compare data from more than two groups from single and multiple days, one-way
398 and two-way ANOVA with Tukey's post-hoc multiple comparison test were used for the

399 analysis, respectively. Western blotting and IL-1 β data between two groups were analyzed
400 using the Wilcoxon signed-rank test. Other data between two groups were analyzed using
401 paired t-tests. All data are expressed as the mean \pm standard error. Statistical significance
402 was set at P <0.05.

403

404 **References**

- 405 1 Fayaz, A., Croft, P., Langford, R. M., Donaldson, L. J. & Jones, G. T. Prevalence
406 of chronic pain in the UK: a systematic review and meta-analysis of population
407 studies. *BMJ open* **6**, e010364, doi:10.1136/bmjopen-2015-010364 (2016).
- 408 2 Hanvold, T. N. *et al.* The effect of work-related sustained trapezius muscle activity
409 on the development of neck and shoulder pain among young adults. *Scandinavian*
410 *journal of work, environment & health* **39**, 390-400, doi:10.5271/sjweh.3357
411 (2013).
- 412 3 van Dieen, J. H., Selen, L. P. & Cholewicki, J. Trunk muscle activation in low-
413 back pain patients, an analysis of the literature. *Journal of electromyography and*
414 *kinesiology : official journal of the International Society of Electrophysiological*
415 *Kinesiology* **13**, 333-351, doi:10.1016/s1050-6411(03)00041-5 (2003).
- 416 4 Borg-Stein, J. & Simons, D. G. Focused review: myofascial pain. *Archives of*
417 *physical medicine and rehabilitation* **83**, S40-47, S48-49,
418 doi:10.1053/apmr.2002.32155 (2002).
- 419 5 Punnett, L. & Wegman, D. H. Work-related musculoskeletal disorders: the
420 epidemiologic evidence and the debate. *Journal of electromyography and*
421 *kinesiology : official journal of the International Society of Electrophysiological*
422 *Kinesiology* **14**, 13-23, doi:10.1016/j.jelekin.2003.09.015 (2004).
- 423 6 Mills, S. E. E., Nicolson, K. P. & Smith, B. H. Chronic pain: a review of its
424 epidemiology and associated factors in population-based studies. *British journal*
425 *of anaesthesia* **123**, e273-e283, doi:10.1016/j.bja.2019.03.023 (2019).
- 426 7 Mense, S. Muscle pain: mechanisms and clinical significance. *Deutsches*
427 *Arzteblatt international* **105**, 214-219, doi:10.3238/artzebl.2008.0214 (2008).
- 428 8 Mastaglia, F. L. The relationship between muscle pain and fatigue.

- 429 *Neuromuscular disorders* : *NMD* **22** **Suppl 3**, S178-180,
430 doi:10.1016/j.nmd.2012.10.003 (2012).
- 431 9 Dubin, A. E. & Patapoutian, A. Nociceptors: the sensors of the pain pathway. *The*
432 *Journal of clinical investigation* **120**, 3760-3772, doi:10.1172/JCI42843 (2010).
- 433 10 Shinoda, M., Ozaki, N. & Sugiura, Y. Involvement of ATP and its receptors on
434 nociception in rat model of masseter muscle pain. *Pain* **134**, 148-157,
435 doi:10.1016/j.pain.2007.04.006 (2008).
- 436 11 Yoshida, S. *et al.* Involvement of inflammasome activation via elevation of uric
437 acid level in nociception in a mouse model of muscle pain. *Molecular pain* **15**,
438 1744806919858797, doi:10.1177/1744806919858797 (2019).
- 439 12 Retamoso, L. T. *et al.* Increased xanthine oxidase-related ROS production and
440 TRPV1 synthesis preceding DOMS post-eccentric exercise in rats. *Life sciences*
441 **152**, 52-59, doi:10.1016/j.lfs.2016.03.029 (2016).
- 442 13 Green, H. J. & Fraser, I. G. Differential effects of exercise intensity on serum uric
443 acid concentration. *Med Sci Sports Exerc* **20**, 55-59, doi:10.1249/00005768-
444 198802000-00008 (1988).
- 445 14 Kono, H., Chen, C. J., Ontiveros, F. & Rock, K. L. Uric acid promotes an acute
446 inflammatory response to sterile cell death in mice. *The Journal of clinical*
447 *investigation* **120**, 1939-1949, doi:10.1172/JCI40124 (2010).
- 448 15 Chen, R., Yin, C., Fang, J. & Liu, B. The NLRP3 inflammasome: an emerging
449 therapeutic target for chronic pain. *Journal of neuroinflammation* **18**, 84,
450 doi:10.1186/s12974-021-02131-0 (2021).
- 451 16 Braga, T. T. *et al.* Soluble Uric Acid Activates the NLRP3 Inflammasome.
452 *Scientific reports* **7**, 39884, doi:10.1038/srep39884 (2017).
- 453 17 Yoshida, S. *et al.* Involvement of neutrophils and interleukin-18 in nociception in
454 a mouse model of muscle pain. *Molecular pain* **14**, 1744806918757286,
455 doi:10.1177/1744806918757286 (2018).
- 456 18 Kastner, D. L., Aksentjevich, I. & Goldbach-Mansky, R. Autoinflammatory
457 disease reloaded: a clinical perspective. *Cell* **140**, 784-790,
458 doi:10.1016/j.cell.2010.03.002 (2010).
- 459 19 Mutua, V. & Gershwin, L. J. A Review of Neutrophil Extracellular Traps (NETs)
460 in Disease: Potential Anti-NETs Therapeutics. *Clinical reviews in allergy &*
461 *immunology*, doi:10.1007/s12016-020-08804-7 (2020).
- 462 20 Punzi, L., Scanu, A., Ramonda, R. & Oliviero, F. Gout as autoinflammatory
463 disease: new mechanisms for more appropriated treatment targets. *Autoimmunity*
464 *reviews* **12**, 66-71, doi:10.1016/j.autrev.2012.07.024 (2012).

- 465 21 Bodofsky, S., Merriman, T. R., Thomas, T. J. & Schlesinger, N. Advances in our
466 understanding of gout as an auto-inflammatory disease. *Seminars in arthritis and*
467 *rheumatism* **50**, 1089-1100, doi:10.1016/j.semarthrit.2020.06.015 (2020).
- 468 22 Neubert, E. *et al.* Chromatin swelling drives neutrophil extracellular trap release.
469 *Nature communications* **9**, 3767, doi:10.1038/s41467-018-06263-5 (2018).
- 470 23 Cicco, S., Cicco, G., Racanelli, V. & Vacca, A. Neutrophil Extracellular Traps
471 (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential
472 Targets for COVID-19 Treatment. *Mediators of inflammation* **2020**, 7527953,
473 doi:10.1155/2020/7527953 (2020).
- 474 24 Sumagin, R., Prizant, H., Lomakina, E., Waugh, R. E. & Sarelius, I. H. LFA-1 and
475 Mac-1 define characteristically different intraluminal crawling and emigration
476 patterns for monocytes and neutrophils in situ. *Journal of immunology (Baltimore,*
477 *Md. : 1950)* **185**, 7057-7066, doi:10.4049/jimmunol.1001638 (2010).
- 478 25 Syu, G. D., Chen, H. I. & Jen, C. J. Acute severe exercise facilitates neutrophil
479 extracellular trap formation in sedentary but not active subjects. *Med Sci Sports*
480 *Exerc* **45**, 238-244, doi:10.1249/MSS.0b013e31826df4a1 (2013).
- 481 26 Gray, R. D. *et al.* Delayed neutrophil apoptosis enhances NET formation in cystic
482 fibrosis. *Thorax* **73**, 134-144, doi:10.1136/thoraxjnl-2017-210134 (2018).
- 483 27 Kataoka, H., Yang, K. & Rock, K. L. The xanthine oxidase inhibitor Febuxostat
484 reduces tissue uric acid content and inhibits injury-induced inflammation in the
485 liver and lung. *European journal of pharmacology* **746**, 174-179,
486 doi:10.1016/j.ejphar.2014.11.013 (2015).
- 487 28 Martillo, M. A., Nazzari, L. & Crittenden, D. B. The crystallization of monosodium
488 urate. *Current rheumatology reports* **16**, 400, doi:10.1007/s11926-013-0400-9
489 (2014).
- 490 29 Randall, L. O. & Selitto, J. J. A method for measurement of analgesic activity on
491 inflamed tissue. *Archives internationales de pharmacodynamie et de therapie* **111**,
492 409-419 (1957).
- 493 30 Ju, T.-J., Dan, J.-M., Cho, Y.-J. & Park, S.-Y. Inhibition of Inducible Nitric Oxide
494 Synthase Attenuates Monosodium Urate-induced Inflammation in Mice. *kjpp* **15**,
495 363-369, doi:10.4196/kjpp.2011.15.6.363 (2011).
- 496 31 Chen, C.-J. *et al.* MyD88-dependent IL-1 receptor signaling is essential for gouty
497 inflammation stimulated by monosodium urate crystals. *The Journal of clinical*
498 *investigation* **116**, 2262-2271, doi:10.1172/JCI28075 (2006).
- 499 32 Cagliani, J., Yang, W. L., Brenner, M. & Wang, P. Deoxyribonuclease Reduces
500 Tissue Injury and Improves Survival After Hemorrhagic Shock. *The Journal of*

- 501 *surgical research* **249**, 104-113, doi:10.1016/j.jss.2019.11.036 (2020).
- 502 33 Wang, S. *et al.* Febuxostat pretreatment attenuates myocardial
503 ischemia/reperfusion injury via mitochondrial apoptosis. *Journal of translational*
504 *medicine* **13**, 209, doi:10.1186/s12967-015-0578-x (2015).
- 505 34 Chen, L., Watanabe, T., Watanabe, H. & Sendo, F. Neutrophil depletion
506 exacerbates experimental Chagas' disease in BALB/c, but protects C57BL/6 mice
507 through modulating the Th1/Th2 dichotomy in different directions. *European*
508 *journal of immunology* **31**, 265-275, doi:10.1002/1521-
509 4141(200101)31:1<265::Aid-immu265>3.0.Co;2-l (2001).
- 510 35 Hirano, Y. *et al.* Neutralization of osteopontin attenuates neutrophil migration in
511 sepsis-induced acute lung injury. *Critical care (London, England)* **19**, 53,
512 doi:10.1186/s13054-015-0782-3 (2015).
- 513 36 Conlan, J. W. & North, R. J. Neutrophils are essential for early anti-Listeria
514 defense in the liver, but not in the spleen or peritoneal cavity, as revealed by a
515 granulocyte-depleting monoclonal antibody. *The Journal of experimental*
516 *medicine* **179**, 259-268, doi:10.1084/jem.179.1.259 (1994).
- 517 37 Rakhmilevich, A. L. Neutrophils are essential for resolution of primary and
518 secondary infection with *Listeria monocytogenes*. *Journal of leukocyte biology*
519 **57**, 827-831, doi:10.1002/jlb.57.6.827 (1995).
- 520 38 Chaweewannakorn, C. *et al.* Exercise-evoked intramuscular neutrophil-
521 endothelial interactions support muscle performance and GLUT4 translocation: a
522 mouse gnawing model study. *The Journal of physiology* **598**, 101-122,
523 doi:10.1113/JP278564 (2020).
- 524 39 Masuda, S. *et al.* Measurement of NET formation in vitro and in vivo by flow
525 cytometry. *Cytometry. Part A : the journal of the International Society for*
526 *Analytical Cytology* **91**, 822-829, doi:10.1002/cyto.a.23169 (2017).
- 527 40 Chaweewannakorn, C. *et al.* Imaging of muscle activity-induced morphometric
528 changes in fibril network of myofascia by two-photon microscopy. *Journal of*
529 *anatomy* **238**, 515-526, doi:10.1111/joa.13339 (2021).
- 530 41 Tsuchiya, M. *et al.* Neutrophils Provide a Favorable IL-1-Mediated
531 Immunometabolic Niche that Primes GLUT4 Translocation and Performance in
532 Skeletal Muscles. *Cell reports* **23**, 2354-2364, doi:10.1016/j.celrep.2018.04.067
533 (2018).

534

535 Acknowledgments

536 The authors are grateful to Dr. Shigenori Sekiai, Dr. Chayanit Chaweewannakorn, and
537 Ms. Natsumi Emoto at the Tohoku University Graduate School of Biomedical
538 Engineering for their technical assistance and Dr. Hiroyuki Tada at the Tohoku
539 University Graduate School of Dentistry for the excellent advice on the study. We also
540 thank other doctors at the Department of Orthopaedic Surgery, Tohoku University
541 Graduate School of Medicine, for their excellent technical advice in this study.

542

543 **Authors' contributions**

544 Conceptualization: KS, MT, SY, MK, and YH; Data curation: KS, MT, and KO; Formal
545 analysis: KS and MT; Funding acquisition: MT, SY, MK, and YH; Investigation: KS,
546 SY, KO, WC, TT, RF, and YL; Methodology: KS, MT, WC, MK, and YL; Project
547 administration: MT, SY, MK, YY, and YH; Resources: KS, MT, SY, KO, WC, TT, RF,
548 and YL; Supervision: MK, TA, and YH; Validation: TT, RF, and YL; Writing – original
549 draft: KS, MT, SY, and YH. All authors contributed to the data analysis and work
550 presented in this paper.

551

552 **Declarations**

553 **Ethics approval and consent to participate**

554 The experimental design, care, and use of the mice were performed according to the
555 guidelines for animal experiments at Tohoku University. Ethical approval for this study
556 was obtained from the Animal Research Committee of Tohoku University (approval
557 number: 2019 MdA-070).

558 **Consent for publication**

559 Not applicable

560 **Availability of data and materials**

561 The data that support the findings of this study are available from the corresponding
562 author, MT, upon reasonable request.

563 **Competing interests**

564 The authors declare that they have no competing interests.

565 **Funding**

566 This work was supported in part by grants from the Japan Society for the Promotion of
567 Science (nos. 16K11580 and 19K10229 to MT).

568

569 **Figure Legends**

570 **Figure 1.** Induction of muscle hyperalgesia and NETs with intramuscular MSU injection.

571 (a) Time-series experiment of MNT values in the MSU- or Saline-injected (contralateral)

572 hindlimbs. (b) Representative IHC images of TSM tissue on day 2, indicating citH3
573 (green), Gr-1 (red), and DAPI (blue). Western blotting analysis of citH3 (c) and Ly6G (d)
574 amounts in TSM tissues on day 2 after intramuscular injection of MSU or Saline. The
575 relative density is normalized based on the loading control (total histone H3: total H3 and
576 GAPDH, respectively). Scale bar = 100 μ m. (e) qRT-PCR analysis was performed to
577 evaluate expression levels of IL-1 β , using MSU- or saline-injected TSM tissues on day 2.
578 All data are shown as mean \pm SE (n = 6 - 10) and analysed using paired t-test or two-way
579 ANOVA with Tukey's post-hoc multiple comparison test for time-series of MNT values.
580 Statistical significance is indicated with * (p < 0.05), ** (p < 0.01) and *** (p < 0.001),
581 respectively.

582

583 **Figure 2.** Effects of repeated electrical stimulation (EPS) to induce muscle hyperalgesia
584 and NETs. (a) Time series experiment of MNT values in the stimulated and non-
585 stimulated hindlimbs (contralateral side in the same mice). (b) The uric acid level in the
586 stimulated and non-stimulated TSM tissues on day 7. (c) Representative IHC images of
587 mouse TSM tissue with or without repeated EPS on day 7, indicating citH3 (green), Gr-
588 1 (red), and DAPI (blue). Scale bar = 100 μ m. (d) citH3 and (e) Ly6G amounts in TSM
589 tissues with or without repeated EPS on day 7 by western blotting analysis. The relative

590 density is normalized based on the loading control (total histone H3: total H3 and GAPDH,
591 respectively). (f) Time series experiment of citH3 induction in stimulated TSM tissues.
592 After normalization of citH3 using the total H3, a ratio of citH3 in ipsilateral side relative
593 to contralateral side was calculated in each individual. (g) qRT-PCR analysis was
594 performed to evaluate expression levels of IL-1 β , using TSM tissues of control or
595 stimulated mice on day 7. All data are shown as mean \pm SE (n = 4 - 9) and analysed using
596 paired t-test for comparing the mean of two different samples or two-way ANOVA
597 followed by Tukey's post-hoc multiple comparison test for time-series experiment of
598 MNT values and for comparing more than two groups. Statistical significance is indicated
599 with * (p < 0.05), ** (p < 0.01) and *** (p < 0.001), respectively.

600

601 **Figure 3.** Effects of DNase treatment on NETs induction associated with muscle
602 hyperalgesia. MNT values of hindlimbs (a) and the uric acid level (b) in TSM tissues in
603 sham-stimulated control and stimulated mice injected intravenously with 10 mg/kg/day
604 of DNase I or a vehicle. (c) Representative IHC images of the stimulated TSM tissue with
605 or without DNase I administration on day 7, indicating citH3 (green), Gr-1 (red), and
606 DAPI (blue). Scale bar = 100 μ m. Western blotting analysis of citH3 (d) and Ly6G (e)
607 amounts in TSM tissues on day 7. The relative density is normalized based on the loading

608 control (total H3 and GAPDH, respectively), and further calculated as a ratio in ipsilateral
609 side relative to contralateral (unstimulated) side of the same individual. (f) qRT-PCR
610 analysis was performed to evaluate expression levels of IL-1 β in TSM tissues on day 7.
611 All data are shown as mean \pm SE (n = 4 - 9) and analysed using unpaired t-test for
612 comparing the mean of two different samples or two-way ANOVA followed by post-hoc
613 Tukey's test for a comparison of more than two groups. Statistical significance is
614 indicated with * (p < 0.05), ** (p < 0.01) and *** (p < 0.001), respectively.

615

616 **Figure 4.** Effects of neutrophil depletion on NETs induction associated with muscle
617 hyperalgesia. MNT values of hindlimbs (a) and the uric acid level (b) in TSM tissues in
618 sham-stimulated control and stimulated mice injected intravenously with 5 mg/kg BW of
619 anti-Gr-1 antibodies or control rat IgGs every 3 days. (c) Representative IHC images of
620 the stimulated TSM tissue with or without neutrophil depletion on day 7, indicating citH3
621 (green), Gr-1 (red), and DAPI (blue). Scale bar = 100 μ m. (d) Western blotting analysis
622 of citH3 amounts in TSM tissues on day 7. The relative density is normalized based on
623 the loading control (total H3), and further calculated as a ratio in ipsilateral side relative
624 to contralateral (unstimulated) side of the same individual. (e) qRT-PCR analysis was
625 performed to evaluate expression levels of IL-1 β in TSM tissues on day 7. All data are

626 shown as mean \pm SE (n = 4 - 8) and analysed using unpaired t-test for comparing the
627 mean of two different samples or two-way ANOVA followed by post-hoc Tukey's test for
628 a comparison of more than two groups. Statistical significance is indicated with * (p <
629 0.05), ** (p < 0.01) and *** (p < 0.001), respectively.

630

631 **Figure 5.** Effects of febuxostat treatment on NETs induction associated with muscle
632 hyperalgesia. MNT values of hindlimbs (a) and the uric acid level (b) in TSM tissues in
633 sham-stimulated control and stimulated mice injected intraperitoneally with 5 mg/kg
634 BW/day of febuxostat or a vehicle. (c) Representative IHC images of the stimulated TSM
635 tissue with or without febuxostat treatment on day 7, indicating citH3 (green), Gr-1 (red),
636 and DAPI (blue). Scale bar = 100 μ m. (d) Western blotting analysis of citH3 amounts in
637 TSM tissues with or without febuxostat treatment on day 7. The relative density is
638 normalized based on the loading control (total H3), and further calculated as a ratio in
639 ipsilateral side relative to contralateral (unstimulated) side of the same individual. (e)
640 qRT-PCR analysis was performed to evaluate expression levels of IL-1 β in TSM tissues
641 on day 7. All data are shown as mean \pm SE (n = 4 - 9) and analysed using unpaired t-test
642 for comparing the mean of two different samples or two-way ANOVA followed by post-
643 hoc Tukey's test for a comparison of more than two groups. Statistical significance is

644 indicated with * ($p < 0.05$), ** ($p < 0.01$) and *** ($p < 0.001$), respectively.

645

646 **Figure 6.** MPM imaging of neutrophil recruitment releasing extracellular DNA due to
647 repeated electrical stimulation (EPS) as assessed by in vivo immunostaining.
648 Representative images show fluorescence colocalization of neutrophils (indicated by
649 white arrows) labelled with QD655-conjugated anti-Gr-1 antibody (red) and extracellular
650 DNA labelled with SYTOX (green) in TSM tissues (muscle fibers and myofascia zone)
651 of sham-control or stimulated mice on day 7. Muscle and collagenous fibers are visualized
652 with second-harmonic generation (blue). The graph summarizing area quantification (%)
653 of fluorescence colocalizations within myofascia or muscle fibers of TSM tissues is
654 indicated. Data are shown as the mean \pm SE ($n = 3$). The quantification results were
655 analysed using one-way ANOVA with Tukey's post hoc test. Scale bar = 50 μ m. Both a
656 and b show significant difference to all other groups at $P < 0.05$, respectively.

657

658 **Figure 7.** A simple schema of the developing pathway of muscle hyperalgesia caused by
659 a higher tissue uric acid level in the mouse model, and the effects of inhibitors at each
660 factor.

661


662 Figure 1

663

664

665

666




667

668

669


670



671

672


673



674




675

676



677

678



679 Figure 2

680

681

682

683

684

685

686

687

688

689

690


691

692


693

694


695




696 Figure 3





712 Figure 4




728 Figure 5



744 Figure 6



760 Figure 7



Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementalmovie1acont.mpg](#)
- [Supplementalmovie1bstimulated.mpg](#)
- [SupplementaryFigure.pdf](#)